Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILE: MRI Assessment of Cardiac and Liver Iron in Anaemic Patients Treated With Exjade (Deferasirox)
2016-000246-62Phase 4
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in hemoglobinopathies, myelodysplastic syndrome (MDS), Diamond-Blackfan anemia (DBA) and 2 more, sponsored by Novartis. Primary endpoint: Change in cardiac iron load and cardiac ejection fraction by MRI.
02
Drugs
deferasirox
03
Conditions
hemoglobinopathiesmyelodysplastic syndrome (MDS)Diamond-Blackfan anemia (DBA)myeloproliferative disorder (MPD)anaemia
Beyond the preview
Go deeper on 2016-000246-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000246-62.